GeoVax to Showcase COVID-19 Vaccine Research at Roth Conference
TL;DR
GeoVax Labs, Inc. announces CEO presentation at Roth Conference, offering investors insight and potential advantage.
GeoVax Labs, Inc. Chairman & CEO, David Dodd, to present at 37th Annual Roth Conference in Dana Point, CA on March 17, 2025.
GeoVax Labs, Inc. develops immunotherapies and vaccines against cancers and infectious diseases, making strides towards a healthier future.
GeoVax Labs, Inc. CEO, David Dodd, to engage in a fireside chat at Roth Conference, presenting cutting-edge biotechnology advancements.
Found this article helpful?
Share it with your network and spread the knowledge!
Biotechnology company GeoVax Labs will present its latest research developments at the 37th Annual Roth Conference in Dana Point, California. Chairman and CEO David Dodd will participate in a fireside chat on March 17, 2025, providing insights into the company's cutting-edge vaccine and oncology programs.
The presentation will spotlight GeoVax's lead clinical program, GEO-CM04S1, a next-generation COVID-19 vaccine. The company recently received a BARDA-funded contract to sponsor a substantial 10,000-participant Phase 2b clinical trial comparing the vaccine's efficacy against existing approved COVID-19 vaccines.
GeoVax's COVID-19 vaccine is currently undergoing three Phase 2 clinical trials with unique focus areas. These trials are evaluating the vaccine as a primary immunization for immunocompromised patients, a booster for chronic lymphocytic leukemia patients, and a more robust booster for individuals who previously received mRNA vaccines.
In addition to its infectious disease research, GeoVax is advancing oncology treatments. The company is evaluating Gedeptin®, an innovative oncolytic solid tumor gene-directed therapy. After completing a multicenter Phase 1/2 clinical trial for advanced head and neck cancers, GeoVax plans a Phase 2 clinical trial combining Gedeptin® with an immune checkpoint inhibitor.
The conference presentation represents an opportunity for investors and researchers to gain deeper understanding of GeoVax's potential contributions to medical science, particularly in addressing challenging medical conditions for vulnerable patient populations.
Curated from NewMediaWire
